Alexion surges on Soliris sales, Irish tax rate
This article was originally published in Scrip
The already high-value Alexion Pharmaceuticals stock reached a new peak price of $162 per share on 30 January after the company reported impressive Soliris (eculizumab) sales gains for 2013 and a 2014 tax rate that will be two-thirds lower than prior expectations based on a move of key operations and intellectual property to corporate tax-friendly Ireland.
You may also be interested in...
Public Company Edition: Codiak, Kiromic, Aligos and Opthea have fallen below their initial public offering values, while Tarsus and Praxis are trading higher. Also, 5AM, MPM and Cormorant took biotech SPACs public and Evotec led recent non-IPO financings with a €250m private placement.
Private Company Edition: Venture capital invested in pharma and biotech in 2020 totaled $19.5m through Q3, just $400m below the full-year record total of $19.9bn in 2018. Also, Canaan and Catalio reveal new VC funds, while Talaris’s $115m series B leads recent financings.
Biopharma executives discussed their strategies for treating chronic diseases during the Cell and Gene Meeting on the Mesa, including R&D and regulatory considerations.